Breaking News Instant updates and real-time market news.

ASMB

Assembly Biosciences

$13.32

-0.55 (-3.97%)

, AGN

Allergan

$164.27

1.67 (1.03%)

07:29
06/27/19
06/27
07:29
06/27/19
07:29

Assembly Biosciences announces first patient dosed in Phase 1b trial of ABI-M201

Assembly Biosciences (ASMB) announced the initiation of dosing in a Phase 1b clinical trial to evaluate ABI-M201 in patients with mildly to moderately active ulcerative colitis. M201 is Assembly's first investigational oral live biotherapeutic product to enter into clinical development, as part of its gastrointestinal focused collaboration with Allergan (AGN). M201 is comprised of a rationally designed consortium of commensal bacteria that were selected based on ability to modulate ulcerative colitis-relevant cellular mechanisms in human cell-based assays and animal models. M201 is orally administered utilizing Assembly's Gemicel capsule-in-capsule delivery system, designed for targeted delivery into the GI tract. The Phase 1b clinical trial is double-blind, placebo-controlled and designed to evaluate the safety and efficacy of M201 administered once daily for eight weeks, in approximately 44 patients with mildly to moderately active UC. Study participants will be enrolled into two sequential non-overlapping cohorts, to evaluate up to two active dose levels. While the primary objective of the study is to assess the safety and tolerability of M201, key efficacy measurements will include clinical remission and endoscopic improvement.

ASMB

Assembly Biosciences

$13.32

-0.55 (-3.97%)

AGN

Allergan

$164.27

1.67 (1.03%)

ASMB Assembly Biosciences
$13.32

-0.55 (-3.97%)

10/08/18
RILY
10/08/18
UPGRADE
Target $42
RILY
Buy
Assembly Biosciences upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar upgraded Assembly Biosciences to Buy with an unchanged price target of $42. The recent pullback in the shares ignores the company's core opportunity in hepatitis B virus, Kumar tells investors in a research note.
11/13/18
JEFF
11/13/18
NO CHANGE
Target $75
JEFF
Buy
Assembly Biosciences shares likely to rally into Phase II data, says Jefferies
Jefferies analyst Michael Yee sees shares of Assembly Biosciences "going back up" into new its Phase II data in the first half of 2019. The company continues to execute on its vision to develop first-in-class and best-in-class core inhibitors, Yee tells investors in a research note. He says that while Street expectations have been lowered on Hepatitis B virus in the past year, interest among key opinion leaders has "only increased as data has been presented and has been notable." The analyst keeps a Buy rating on Assembly Biosciences with a $75 price target.
11/19/18
LEER
11/19/18
INITIATION
Target $45
LEER
Outperform
Assembly Biosciences initiated with an Outperform at Leerink
Leerink analyst Geoffrey Porges started Assembly Biosciences with an Outperform rating and $45 price target. The analyst cited the probability-adjusted value for the cash flows he expects from its lead asset ABI-H0731, which is an oral Core Protein Allosteric Modifier in phase II development for chronic hepatitis B virus. Porges forecasts '731 launching in 2022E and growing to $650M in risk-adjusted revenues.
04/15/19
JMPS
04/15/19
NO CHANGE
Target $116
JMPS
Outperform
Enanta early data on EDP-514 look promising, says JMP Securities
JMP Securities analyst Liisa Bayko said she was impressed with the preclinical data presented by Enanta (ENTA) at the EASL meeting on its HBV core inhibitor candidate EDP-514. When comparing to other core inhibitors in development, EDP-514 "appears at least as potent as the competition" with the exception of Assembly Biosciences' (ASMB) third-generation capsid inhibitor ABI-H3733, said Bayko, who added that EDP-514 has a superior reduction in HBV viral load than ABI-H3733 and a lower EC50 level than Assembly's first- and second-generation inhibitors. Bayko keeps an Outperform rating and $116 price target on Enanta shares.
AGN Allergan
$164.27

1.67 (1.03%)

06/26/19
MZHO
06/26/19
DOWNGRADE
Target $188
MZHO
Neutral
Allergan downgraded to Neutral from Buy at Mizuho
Mizuho analyst Irina Koffler downgraded Allergan (AGN) to Neutral from Buy and raised her price target on the stock to $188 from $171 after AbbVie (ABBV) announced a cash-and-stock deal to buy the company. She views the deal as "a hard-fought and timely exit" for shareholders, citing her concerns about the weakness in Allergan's aesthetics portfolio and the company's growth challenges.
06/26/19
SBSH
06/26/19
NO CHANGE
SBSH
Neutral
AbbVie synergies target for Allergan deal looks achievable, says Citi
Citi analyst Andrew Baum said he believes AbbVie's (ABBV) roughly $2B synergies target for its deal with Allergan (AGN) looks achievable and he thinks the takeover plugs the Humira revenue hole and likely generates long term sustainable growth through Allergan's aesthetic franchise. While he is "more relaxed" about longer-term risks, including AbbVie's potential to underinvest or mismanage the aesthetics business or erosion of Botox market share, he sees near-term risks that include the impact of a potential U.S. Enbrel biosimilar launch on Humira revenues, and therefore AbbVie's credit rating, as well as Allergan's near-term non-GAAP outlook given the company's "poor guidance track record." Baum keeps a Neutral rating on AbbVie shares.
06/26/19
06/26/19
UPGRADE
Target $88

Outperform
AbbVie upgraded to Outperform after Allergan acquisition at SVB Leerink
As previously reported, SVB Leerink analyst Geoffrey Porges upgraded AbbVie (ABBV) to Outperform from Market Perform, with an $88 price target, after the "surprise" Allergan (AGN) acquisition announcement, and the stock's 16%-plus selloff intraday. The analyst notes that the loss of value in AbbVie exceeded the value of the premium the company's offer put on Allergan's value prior to the announcement. Porges also cited AbbVie's new dividend yield of 6.5%, the sustainability and likely growth of that dividend through 2023 and the high probability that AbbVie will extract even more synergies from Allergan than was suggested.
06/26/19
06/26/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. State Street (STT) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying he has "very little confidence" in when the company will be able to get past the headwinds it is facing. 2. Allergan (AGN) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying she views the AbbVie (ABBV) deal as "a hard-fought and timely exit" for shareholders, citing her concerns about the weakness in Allergan's aesthetics portfolio and the company's growth challenges. 3. Kinder Morgan (KMI) downgraded to Market Perform from Outperform at Raymond James with analyst Justin Jenkins saying shares are up approximately 35% year-to-date and trade at an above-peer multiple despite a mixed outlook for the asset portfolio. 4. Papa John's (PZZA) downgraded to Neutral from Buy at Kalinowski. 5. Illinois Tool Works (ITW) downgraded to Sell from Neutral at Northcoast with the firm's analyst citing concentrated Automotive exposure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

09:00
07/18/19
07/18
09:00
07/18/19
09:00
General news
Treasury Action: yields have cheapened »

Treasury Action: yields…

09:00
07/18/19
07/18
09:00
07/18/19
09:00
General news
The 8k initial claims rise to 216k »

The 8k initial claims…

EGHT

8x8, Inc.

$24.60

-0.44 (-1.76%)

08:57
07/18/19
07/18
08:57
07/18/19
08:57
Recommendations
8x8, Inc. analyst commentary  »

8x8, Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 01

    Aug

  • 13

    Nov

UAL

United Continental

$94.83

0.83 (0.88%)

, LUV

Southwest

$52.31

-0.97 (-1.82%)

08:56
07/18/19
07/18
08:56
07/18/19
08:56
Recommendations
United Continental, Southwest, Delta Air Lines analyst commentary  »

Stephens surprised United…

UAL

United Continental

$94.83

0.83 (0.88%)

LUV

Southwest

$52.31

-0.97 (-1.82%)

DAL

Delta Air Lines

$62.24

-0.93 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 13

    Nov

  • 12

    Dec

HON

Honeywell

$168.81

-6 (-3.43%)

08:55
07/18/19
07/18
08:55
07/18/19
08:55
Hot Stocks
Honeywell says expects 'continued strong performance' in Aerospace in Q3 »

Says: Many macro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

AMD

AMD

$33.59

-0.23 (-0.68%)

, NFLX

Netflix

$362.50

-3.22 (-0.88%)

08:55
07/18/19
07/18
08:55
07/18/19
08:55
Options
Notable open interest changes for July 18th »

Wednesday's total…

AMD

AMD

$33.59

-0.23 (-0.68%)

NFLX

Netflix

$362.50

-3.22 (-0.88%)

AMAT

Applied Materials

$46.21

0.21 (0.46%)

TSLA

Tesla

$254.85

2.47 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 06

    Aug

ABT

Abbott

$85.78

2.67 (3.21%)

08:55
07/18/19
07/18
08:55
07/18/19
08:55
Recommendations
Abbott analyst commentary  »

Abbott price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:55
07/18/19
07/18
08:55
07/18/19
08:55
General news
U.S. equities are mildly weaker »

U.S. equities are mildly…

08:55
07/18/19
07/18
08:55
07/18/19
08:55
Conference/Events
House Judiciary Committee to hold a hearing »

The Subcommittee on…

MNKD

MannKind

$1.04

-0.055 (-5.05%)

08:54
07/18/19
07/18
08:54
07/18/19
08:54
Hot Stocks
MannKind repays maturing debt obligation »

MannKind Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,992.41

-17.59 (-0.88%)

08:54
07/18/19
07/18
08:54
07/18/19
08:54
Periodicals
Amazon's Go outlets in Chicago falling short of expectations, Bloomberg reports »

Amazon's Go…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

WP

Worldpay

$132.28

1.07 (0.82%)

08:52
07/18/19
07/18
08:52
07/18/19
08:52
Initiation
Worldpay initiated  »

Worldpay assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONEXF

Onex

$0.00

(0.00%)

08:52
07/18/19
07/18
08:52
07/18/19
08:52
Hot Stocks
Onex to sell Jack's Family Restaurants, terms not disclosed »

Onex Corporation and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$39.03

-0.87 (-2.18%)

, FB

Facebook

$201.97

-1.9 (-0.93%)

08:51
07/18/19
07/18
08:51
07/18/19
08:51
Recommendations
eBay, Facebook analyst commentary  »

eBay price target raised…

EBAY

eBay

$39.03

-0.87 (-2.18%)

FB

Facebook

$201.97

-1.9 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

WEX

Wex

$218.50

0.11 (0.05%)

08:51
07/18/19
07/18
08:51
07/18/19
08:51
Initiation
Wex initiated  »

Wex assumed with a Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOK

MyoKardia

$49.90

-0.21 (-0.42%)

08:50
07/18/19
07/18
08:50
07/18/19
08:50
Hot Stocks
MyoKardia expects cash, cash equivalents to fund operations into 2H21 »

MyoKardia's cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

V

Visa

$179.16

-0.14 (-0.08%)

08:50
07/18/19
07/18
08:50
07/18/19
08:50
Initiation
Visa initiated  »

Visa assumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

TSS

TSYS

$133.04

0.06 (0.05%)

08:50
07/18/19
07/18
08:50
07/18/19
08:50
Initiation
TSYS initiated  »

TSYS assumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIR

Circor

$37.12

-1.22 (-3.18%)

08:50
07/18/19
07/18
08:50
07/18/19
08:50
Upgrade
Circor rating change  »

Circor upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

MYOK

MyoKardia

$49.90

-0.21 (-0.42%)

, SNY

Sanofi

$41.57

-0.25 (-0.60%)

08:49
07/18/19
07/18
08:49
07/18/19
08:49
Hot Stocks
MyoKardia re-acquires U.S. royalty rights to HCM programs from Sanofi »

MyoKardia (MYOK)…

MYOK

MyoKardia

$49.90

-0.21 (-0.42%)

SNY

Sanofi

$41.57

-0.25 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 02

    Oct

SQ

Square

$80.81

0.23 (0.29%)

08:49
07/18/19
07/18
08:49
07/18/19
08:49
Initiation
Square initiated at Jefferies »

Square assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

TMDI

Titan Medical

$2.19

-0.025 (-1.13%)

08:49
07/18/19
07/18
08:49
07/18/19
08:49
Hot Stocks
Titan Medical completes GLP procedures with single-port robotic surgery system »

Titan Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$118.80

-0.88 (-0.74%)

08:49
07/18/19
07/18
08:49
07/18/19
08:49
Initiation
PayPal initiated at Jefferies »

PayPal assumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

MYOK

MyoKardia

$49.90

-0.21 (-0.42%)

08:48
07/18/19
07/18
08:48
07/18/19
08:48
Hot Stocks
MyoKardia expects to report topline data from EXPLORER-HCM trial in 2Q20 »

MyoKardia announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MA

MasterCard

$275.34

-1.1 (-0.40%)

08:48
07/18/19
07/18
08:48
07/18/19
08:48
Initiation
MasterCard initiated at Jefferies »

MasterCard assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.